5 Key Takeaways
-
1
The FDA authorized the Valeda Light Delivery System for treating dry AMD using photobiomodulation (PBM) based on LIGHTSITE III trial results.
-
2
The LIGHTSITE III trial showed a statistically significant improvement in best-corrected visual acuity for the PBM group compared to the sham group.
-
3
PBM treatment did not significantly change subretinal pigment epithelial macular drusen volume, while the sham group showed an increase.
-
4
Concerns exist regarding the clinical relevance of PBM's visual acuity improvements, as they may not meet the minimal clinically important difference.
-
5
Systematic reviews indicate PBM lacks meaningful anatomical improvement in drusen volume and geographic atrophy progression in intermediate AMD.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
